During the past decade, Envision Ocular LLC conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 2 clinical trials were completed, i.e. on average, 18.2% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 2 clinical trials were completed. i.e. 28.6% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Envision Ocular LLC" are "Diabetic Macular Edema" (2 trials), "Diabetic Retinopathy" (2 trials), "Geographic Atrophy" (2 trials), "Macular Degeneration, Age-Related" (2 trials) and "Neovascular Age-Related Macular Degeneration" (2 trials). Many other conditions were trialed in "Envision Ocular LLC" in a lesser frequency.

Most popular intervention types in "Envision Ocular LLC" are "Drug" (11 trials), "Other" (2 trials), "Device" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Galegenimab" (2 trials), "Intravitreal Ranibizumab 0.5 mg Injection" (2 trials), "PDS Implant Pre-Filled with 100 mg/mL Ranibizumab" (2 trials), "Aflibercept" (1 trials) and "Faricimab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Envision Ocular LLC" are 11 trials for "All" genders.

Currently, there are NaN active trials in "Envision Ocular LLC". undefined are not yet recruiting, 3 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Envision Ocular LLC, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Envision Ocular LLC, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".